177 related articles for article (PubMed ID: 35579777)
1. A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.
Gong C; Cheng Z; Yang Y; Shen J; Zhu Y; Ling L; Lin W; Yu Z; Li Z; Tan W; Zheng C; Zheng W; Zhong J; Zhang X; Zeng Y; Liu Q; Huang RS; Komorowski AL; Yang ES; Bertucci F; Ricci F; Orlandi A; Franceschini G; Takabe K; Klimberg S; Ishii N; Toss A; Tan MP; Cherian MA; Song E
Sci China Life Sci; 2022 Nov; 65(11):2205-2217. PubMed ID: 35579777
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
4. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
5. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
6. Radiomic signatures derived from multiparametric MRI for the pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer.
Bian T; Wu Z; Lin Q; Wang H; Ge Y; Duan S; Fu G; Cui C; Su X
Br J Radiol; 2020 Nov; 93(1115):20200287. PubMed ID: 32822542
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
8. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract][Full Text] [Related]
9. Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators.
Wang H; Lu Y; Li Y; Li S; Zhang X; Geng C
Curr Probl Cancer; 2022 Dec; 46(6):100914. PubMed ID: 36351312
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
11. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
Jiang M; Li CL; Luo XM; Chuan ZR; Lv WZ; Li X; Cui XW; Dietrich CF
Eur J Cancer; 2021 Apr; 147():95-105. PubMed ID: 33639324
[TBL] [Abstract][Full Text] [Related]
13. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
14. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
15. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
17. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
18. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
[No Abstract] [Full Text] [Related]
19. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
